Sun Pharma raises Rs 1,000 cr via NCDs
New Delhi: Drug major Sun Pharma Industries said it has raised Rs 1,000 crore through issuance of non-convertible debentures (NCDs) on private placement basis. "Sun Pharma Laboratories Ltd, a wholly-owned subsidiary of the company, has raised, on private placement basis, Rs 1,000 crore by allotment of 10,000 unsecured redeemable non-convertible debentures of a face value of Rs 10,00,000...
Login or Register to read the full article
New Delhi: Drug major Sun Pharma Industries said it has raised Rs 1,000 crore through issuance of non-convertible debentures (NCDs) on private placement basis.
"Sun Pharma Laboratories Ltd, a wholly-owned subsidiary of the company, has raised, on private placement basis, Rs 1,000 crore by allotment of 10,000 unsecured redeemable non-convertible debentures of a face value of Rs 10,00,000 each," Sun Pharmaceutical Industries said in a BSE filing.
It further said: "NCDs will be listed on BSE Ltd under two series with Series 1 debentures comprising 5,000 debentures amounting to Rs 500 crore with a tenor of 24 months, and Series 2 debentures comprising 5,000 debentures amounting to Rs 500 crore with a tenor of 39 months."
The company did not elaborate on the usage of proceeds.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd